Doximity (DOCS), Hinge Health (HNGE), and Omada Health (OMDA): Diverging Paths in Digital Health
Key Takeaways
- DOCS (Doximity) is a profitable physician-focused digital network that has bounced off its lows on recent artificial intelligence (AI) product news, yet it still trades far below its 52-week high amid a securities class action and decelerating revenue growth.
- HNGE (Hinge Health) is a digital musculoskeletal (MSK) care platform that has outperformed since its May 2025 initial public offering (IPO), supported by rapid revenue growth and record free cash flow (FCF).
- OMDA (Omada Health) is a virtual cardiometabolic and physical therapy provider that has recently reached modest profitability on a trailing twelve-month (TTM) basis, while carrying a much smaller market capitalization than its peers.
- All three operate in digital health but pursue distinct models: clinician marketing (DOCS), employer-focused MSK care (HNGE), and chronic-condition virtual care (OMDA).
- Relative performance diverges sharply: HNGE shows the strongest recent growth momentum, DOCS the deepest drawdown with legal overhang, and OMDA a steadier but more modest recovery.
Why These Three Stocks Stand Out
Digital health stocks have followed divergent paths in recent months, and few comparisons illustrate that better than Doximity, Hinge Health, and Omada Health. Although all three sell technology-driven healthcare solutions, their business models, growth profiles, and market positioning differ considerably, making them useful case studies for investors evaluating the sector. This stock comparison is relevant for traders seeking relative performance opportunities and for longer-horizon investors weighing momentum, profitability, and risk. By examining recent price behavior, catalysts, and competitive dynamics, readers can assess how each company stacks up in the current market environment without relying on a single headline or price point. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
Doximity (DOCS) Overview and Recent Performance
Doximity operates a digital network for verified medical professionals in the United States, generating most of its revenue through marketing and advertising solutions sold to pharmaceutical companies, health systems, and recruiters. The company has long been regarded as a high-margin, profitable platform with broad physician reach. In recent weeks, however, its relative performance has been shaped by two competing forces. On one side, a securities class action alleging that the company overstated engagement and revenue contributions from its Newsfeed product has weighed on sentiment, alongside slowing revenue growth that led to reduced guidance earlier in the fiscal year. On the other side, fresh AI developments—including a partnership to integrate evidence-based clinical content into its "Ask" assistant—have renewed investor interest and helped shares recover from their lows. The stock remains well below prior highs, leaving its market positioning balanced between a rebounding narrative and unresolved legal and growth questions. From what I see, this balance makes DOCS a name worth monitoring closely.
Hinge Health (HNGE) Overview and Recent Performance
Hinge Health provides a digital health platform focused on musculoskeletal care, covering acute injury, chronic pain, and post-surgical rehabilitation. Its offering combines AI-powered motion tracking with a proprietary nerve stimulation wearable and is sold primarily to self-insured employers and health plans on a software-as-a-service (SaaS) subscription basis. Since its May 2025 IPO, the company has delivered comparatively strong results, including a more than 50% year-over-year revenue increase in its most recent quarter, gross margin near 80%, and record free cash flow, alongside rising client and member counts. This execution has helped the stock outperform the broader market since listing and has attracted notable institutional interest. In recent market activity, HNGE has maintained upward momentum, positioning it as the growth-oriented name among the three. I also checked this using Tickeron’s AI Trend Prediction Engine to evaluate the strength of the recent uptrend.
Omada Health (OMDA) Overview and Recent Performance
Omada Health provides virtual care programs for chronic conditions, including prediabetes, diabetes, and hypertension, as well as physical therapy through its Physera subsidiary, weight management, and support for members taking glucagon-like peptide-1 (GLP-1) medications. The company serves employers, health plans, and health systems through a combination of direct sales and channel partners. Following its June 2025 IPO, OMDA has traded within a broad range, recovering from its lows but remaining below its post-listing peak. On a trailing twelve-month basis, the company has reached roughly break-even to slightly positive net income, a meaningful milestone for a growth-stage virtual care provider, even as its market capitalization remains substantially smaller than DOCS or HNGE. Its recent stock behavior reflects a steadier, lower-volatility profile than its two peers.
Head-to-Head Comparison
The clearest contrast among these three names is their business model and growth trajectory. Doximity is a mature, profitable advertising-driven network whose challenge is re-accelerating revenue after a period of deceleration, compounded by litigation risk and competition from programmatic and social ad formats. Hinge Health is a high-growth, employer-centric MSK platform with improving unit economics and strong cash generation, though it must sustain growth while managing a large addressable market and competitive healthcare landscape. Omada Health occupies a middle position: it is scaling its cardiometabolic and physical therapy programs and approaching profitability, but its smaller scale and broader condition mix may temper valuation sensitivity.
On momentum, HNGE has shown the most consistent recent strength, DOCS the sharpest rebound off a deep drawdown, and OMDA the most range-bound profile. Risk factors also differ: DOCS carries legal and growth-reacceleration risk; HNGE faces execution and competitive risk in employer benefits; and OMDA must demonstrate durable profitability at scale. Sector exposure is broadly aligned across digital health, but each company's revenue mix—marketing versus care delivery versus chronic-condition management—drives distinct sensitivity to advertising budgets, employer spending, and healthcare utilization trends.
Tickeron AI Assessment
Based on observable trend consistency, stability, and relative positioning, Tickeron's AI would likely favor Hinge Health (HNGE) among these three. Its combination of sustained revenue growth, record free cash flow, and a stock trading with relatively steady upward momentum provides a more coherent trend signal than DOCS, which is recovering but remains overshadowed by litigation and decelerating growth, or OMDA, whose range-bound behavior and smaller scale offer less defined directional momentum. This assessment is probabilistic rather than definitive and reflects current market conditions, which can shift as new catalysts emerge.
Exploring Automated Strategies
In my own analysis of names like these, I often look at Tickeron's AI Trading Bots to see how automated approaches might align with the observed trends in digital health. The platform offers a range of bots with different strategies and timeframes, allowing users to match tools to their specific risk parameters and objectives. This has been a practical addition to my research process for evaluating relative performance across stocks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DOCS in +0.99% Uptrend, advancing for three consecutive days on October 22, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where DOCS advanced for three days, in 214 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 29, 2026. You may want to consider a long position or call options on DOCS as a result. In 49 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for DOCS just turned positive on September 30, 2026. Looking at past instances where DOCS's MACD turned positive, the stock continued to rise in 32 of 43 cases over the following month. The odds of a continued upward trend are 74%.
The 50-day moving average for DOCS moved above the 200-day moving average on October 14, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Aroon Indicator entered an Uptrend today. In 130 of 178 cases where DOCS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DOCS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
DOCS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. DOCS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.497) is normal, around the industry mean (4.198). P/E Ratio (37.100) is within average values for comparable stocks, (13.596). Projected Growth (PEG Ratio) (0.590) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (7.776) is also within normal values, averaging (6.065).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DOCS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement